Search
Displaying 181–190 of 556 for “Retinitis pigmentosa”
-
Eye on the Cure Podcast | Episode 92: Lance Baldo, MD
Eye on the CureLance Baldo, MD, CEO at Beacon Therapeutics, is discussing his company’s gene therapy for XLRP.
-
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
Advocacy Research NewsOn behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Beacon Stories
Lindsey Rambo once believed treatment was meant for someone else. Today, she’s the first participant in a groundbreaking gene therapy trial for LCA5—and her journey is lighting the way for what’s possible in the future of vision research.
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
-
Invisible Disability
When I walk around the neighborhood with my white cane, I still worry about stigma and how people perceive me. I’ve had to remind myself that the cane is a tool to keep me safe.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Research NewsThe company plans to complete BLA submission in early 2026.
-
Eye on the Cure Podcast | Episode 88: Richard Small
Eye on the CureRichard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
-
VISIONS 2026: United in Vision Schedule
The United in Vision 2026 conference unites two prestigious events—the Foundation Fighting Blindness VISIONS conference and the Retina International World Congress—into one extraordinary global gathering. Scheduled from Wednesday, June 10 to Saturday, June 13, 2026, at the Fort Worth Convention Center in Fort Worth, Texas,
-
José-Alain Sahel Awarded 2026 ARVO Proctor Medal for Groundbreaking Research Achievements
Research NewsDr. Sahel’s research has led to several emerging retinal disease therapies that have moved into clinical trials.
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
